1. Application! a) neurogenic CNS lipids,! b) L-amino acids of arginine (Arg) or lysine (Lys) and leucine (Leu),! c) trace elements chromium (Cr), tin (Sn), selenium (Se), strontium (Sr), vanadium (V) and tungsten (W), as well! g) folic acid! in the manufacture of a pharmaceutical composition for the treatment or prevention of non-infectious inflammation associated with diseases selected from the group consisting of fibromyalgia, Crohn's disease and rheumatoid arthritis. ! 2. The use according to claim 1, characterized in that the pharmaceutical composition also contains zinc (Zn). ! 3. The use according to claim 1 or 2, characterized in that the pharmaceutical composition also contains manganese (Mn). ! 4. The use according to claim 1, characterized in that the pharmaceutical composition contains:! a) neurogenic CNS lipids,! b) from 2 to 5 g of each of L-arginine hydrochloride and L-leucine,! c) from 0.5 to 9 mg of salts of each of chromium (Cr), tin (Sn), selenium (Se), strontium (Sr), vanadium (V) and tungsten (W), and also! g) from 1 to 2 mg of folic acid. ! 5. The use according to claim 1, characterized in that the pharmaceutical composition is in powder form. ! 6. The use according to claim 1, characterized in that the pharmaceutical composition is in the form of a functional dietary supplement. ! 7. The use according to claim 1, characterized in that the pharmaceutical composition also contains serine (Ser) and isoleucine (He). ! 8. Pharmaceutical composition, characterized in that it contains as the only pharmaceutically active ingredients:! a) neurogenic CNS lipids,! b) L-amino acids arginine (Arg) or lysine (Lys) and leucine (Leu),! c) trace elements chromium (Cr), tin (Sn), selenium (Se), strontium (Sr), vanadium (V), tungsten (W), zinc (Zn) and manganese (Mn), �1. Применение ! а) нейрогенных ЦНС-липидов, ! б) L-аминокислот аргинина (Arg) или лизина (Lys) и лейцина (Leu), ! в) микроэлементов хрома (Cr), олова (Sn), селена (Se), стронция (Sr), ванадия (
